Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: A commentary

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8564-8565

  Abrams, Judith ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; COLON TUMOR; MULTIMODALITY CANCER THERAPY; NOTE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 33644835318     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6186     Document Type: Editorial

References (6)

1. Sargent DF, Wieand S, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005
2. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:411-440, 1989
3. Freedman LS, Graubard BL, Schatzkin A: Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178, 1992
4. Buyse M, Molenberghs G: Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029, 1998
5. Biomarkers Definitions Working Group: Commentary: Biomarkers and surrogate endpoints-Preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95, 2001
6. Molenberghs G, Buyse M, Geys H, et al: Statistical challenges in the evaluation of surrogate endpoints in randomized trials. Control Clin Trials 23:607-625, 2002